Literature DB >> 11532074

Development of potent glucagon antagonists: structure-activity relationship study of glycine at position 4.

J M Ahn1, M Medeiros, D Trivedi, V J Hruby.   

Abstract

We examined the functional role of glycine at position 4 in the potent glucagon antagonist [desHis(1), Glu(9)]glucagon amide, by substituting the L- and D-enantiomers of alanine and leucine for Gly(4) in this antagonist. The methyl and isobutyl side-chain substituents were introduced to evaluate the preference shown by the glucagon receptor, if any, for the orientation of the N-terminal residues. The L-amino acids demonstrated only slightly better receptor recognition than the D-enantiomers. These results suggest that the Gly(4) residue in glucagon antagonists may be exposed to the outside of the receptor. The enhanced binding affinities of analogs 1 and 3 compared with the parent antagonist, [desHis(1), Glu(9)]glucagon amide, may have resulted from the strengthened hydrophobic patch in the N-terminal region and/or the increased propensity for a helical conformation due to the replacement of alanine and leucine for glycine. Thus, as a result of the increased receptor binding affinities, antagonist activities of analogs 1-4 were increased 10-fold compared with the parent antagonist, [desHis(1), Glu(9)]glucagon amide. These potent glucagon antagonists have among the highest pA(2) values of any glucagon analogs reported to date.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11532074     DOI: 10.1034/j.1399-3011.2001.00880.x

Source DB:  PubMed          Journal:  J Pept Res        ISSN: 1397-002X


  2 in total

1.  Recent Progress in the Use of Glucagon and Glucagon Receptor Antago-nists in the Treatment of Diabetes Mellitus.

Authors:  Mohamed Lotfy; Huba Kalasz; Gyorgy Szalai; Jaipaul Singh; Ernest Adeghate
Journal:  Open Med Chem J       Date:  2014-12-31

Review 2.  Proglucagon-Derived Peptides as Therapeutics.

Authors:  Ryan A Lafferty; Finbarr P M O'Harte; Nigel Irwin; Victor A Gault; Peter R Flatt
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-18       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.